PPPT Compounds Inhibit 11β-HSD1 for Metabolic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic syndrome, type 2 diabetes, obesity, and related disorders, such as cardiovascular diseases and cognitive impairments, are limited by the lack of effective inhibitors for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), particularly those with improved pharmacokinetic and microsomal stability.
Innovation Solution
Development of (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds (PPPT compounds) that specifically inhibit 11β-HSD1, offering enhanced pharmacokinetic properties and stability, which are used in pharmaceutical compositions to treat metabolic syndrome, type 2 diabetes, obesity, and CNS disorders like Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for metabolic syndrome are used, then existing therapeutic options are available, but effective inhibitors for 11β-HSD1 with improved pharmacokinetic and microsomal stability are lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of 11β-HSD1 inhibitors to achieve improved pharmacokinetic and microsomal stability. Specifically, the PPPT compounds incorporate structural modifications including the piperidinyl-thiophenone-pyrazole scaffold with various substituents (R1-R6 groups) that optimize metabolic stability while maintaining enzymatic inhibition effectiveness. This resolves the contradiction by changing molecular parameters to simultaneously achieve both reliability of inhibition and stability of the compound.
Solution Approach 2:
The patent employs composite material principles by creating complex multi-component molecular structures that combine different functional groups and structural elements. The PPPT compounds integrate piperidine rings, thiophene cores, pyrazole moieties, and various substituent groups into a composite molecular architecture that provides both potent 11β-HSD1 inhibition and improved pharmacokinetic properties, resolving the contradiction between effectiveness and stability.
2Reliability
If 11β-HSD1 is inhibited to treat metabolic syndrome, then insulin sensitivity improves and gluconeogenesis reduces, but pharmacokinetic stability needs improvement
Solution Approach 1:
The patent uses parameter changes to extend the duration of action by optimizing the pharmacokinetic parameters of the inhibitor molecules. The structural modifications in PPPT compounds, including variations in R1-R6 substituents and core scaffold arrangements, are designed to improve metabolic stability and half-life, thereby extending the duration of therapeutic effect while maintaining insulin sensitivity improvements.
3Reliability
If 11β-HSD1 inhibitors are developed for metabolic disorders, then therapeutic benefits are achieved, but microsomal stability requires enhancement
Solution Approach 1:
The patent applies parameter changes specifically targeted at improving microsomal stability through systematic modification of the inhibitor molecular structure. The PPPT compound series explores various structural parameters including substituent types, positions, and configurations to optimize resistance to microsomal metabolism while preserving therapeutic efficacy for metabolic disorders.
4Reliability
If CNS disorders are treated with 11β-HSD1 inhibition, then cognitive function enhances, but compound stability and bioavailability need improvement
Solution Approach 1:
The patent uses parameter changes to optimize the bioavailability and brain penetration of 11β-HSD1 inhibitors for CNS disorder treatment. The PPPT compounds incorporate structural modifications that improve pharmacokinetic properties including absorption, distribution, and brain tissue penetration, thereby enhancing cognitive function benefits while ensuring adequate bioavailability reaches the central nervous system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PPPT compounds effectively inhibit 11β-HSD1, providing therapeutic benefits for metabolic syndrome, type 2 diabetes, obesity, and cognitive impairments by improving insulin sensitivity, reducing gluconeogenesis, and enhancing cognitive function, while also addressing cardiovascular and lipid disorders.
Implementation Method 1
inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
Data Source
AI summary
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 ß-hydroxysteroid dehydrogenase type 1 (11 ß-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 ß-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 ß-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.